Abstract
After publication of the article, we recently identified after re-reviewing this manuscript that the image from the "Pixel intensity of Aβ 1-40 in hippocampus" in figure 4. B showed overlap with the comparison histogram in figure 4.D due to mistaken figure production. Actually, we aimed to showing the histogram image from "Pixel intensity of Aβ 1-42 in hippocampus" in figure 4. B. The serious mistake was caused by unintentionally and carelessly mistaking the "Comparisons of Aβ 1-40 fragments in hippocampus" instead of "Comparisons of Aβ 1-42 fragments in hippocampus" during figure production. In fact, the careless mistakes do not affect the findings or conclusions of the article.
Introduction
In Alzheimer’s disease (AD), microglia—the primary immune cells of the brain—are tasked with clearing toxic amyloid-beta (Aβ) aggregates. However, chronic inflammation often renders these cells dysfunctional. This study investigates the role of the NLRP3 inflammasome in "microglial training," a form of innate immune memory. While immune training can be protective in other contexts, the authors hypothesized that in AD, inflammatory stimuli "train" microglia through the NLRP3 pathway to become less efficient at clearing Aβ, thereby accelerating cognitive decline.
Methods
The researchers employed several experimental models to test this hypothesis:
- STZ Model: Streptozotocin (STZ) was used to induce an Alzheimer’s-like state in animal models.
- LPS Stimulation: Lipopolysaccharide (LPS) served as a pro-inflammatory stimulus to induce microglial "training."
- NLRP3 Inhibition: The small molecule MCC950 was used to selectively inhibit the NLRP3 inflammasome and observe its effects on Aβ clearance.
- Quantification: The primary outcome measure was the pixel intensity of Aβ 1-42 fragments in the hippocampus, quantified via immunohistochemistry. Aβ 1-42 is a particularly neurotoxic fragment central to AD pathology.
Key Results
The corrected data in Figure 4B provides the quantitative evidence supporting the study's conclusions regarding microglial impairment and the efficacy of NLRP3 inhibition.
Key observations from the corrected data include:
- LPS-Induced Impairment: In the STZ model, the addition of LPS (STZ+LPS) significantly increased Aβ 1-42 pixel intensity compared to the STZ-only group, indicating that inflammatory "training" impairs microglial clearance.
- Therapeutic Potential of NLRP3 Inhibition: Treatment with the inhibitor MCC950 (STZ+MCC950) significantly reduced Aβ 1-42 levels compared to the STZ+LPS group. This suggests that blocking the NLRP3 pathway can restore microglial function and mitigate plaque accumulation.
- Statistical Robustness: The significant differences (indicated by ****) between the STZ+LPS group and both the Sham and STZ+MCC950 groups reinforce NLRP3 as a critical driver of amyloid accumulation in this model.
Discussion and Insights
The study highlights the "double-edged sword" of microglial activation. While initially a defense mechanism, repeated inflammatory training via the NLRP3 inflammasome leads to a state of impaired phagocytosis. By identifying NLRP3 as the master regulator of this dysfunctional state, the research points toward a clear therapeutic target. Distinguishing between Aβ 1-40 and Aβ 1-42 is crucial, as the latter is more prone to forming insoluble, toxic plaques. The corrected figure ensures the data accurately reflects the impact on this more critical fragment.
Limitations and Future Directions
While these findings are promising, several challenges remain for clinical translation:
- Model Translation: Moving from STZ-induced animal models to the complex, long-term progression of human AD is a significant hurdle.
- Intervention Timing: Determining the optimal window for NLRP3 inhibition—whether it is more effective as a preventative measure or a restorative treatment—is a key area for future research.
- Systemic Effects: The broader immune implications of systemic NLRP3 inhibition must be carefully evaluated to avoid off-target effects.
In conclusion, this correction clarifies the quantitative evidence supporting the role of NLRP3-dependent microglial training in Alzheimer's disease progression, reaffirming the study's original conclusions despite the initial figure error.
Summary updated